Low-grade glioma (LGG, WHO grade 2 — IDH-mutant) · line 1 · Radiotherapy + PCV (procarbazine/lomustine/vincristine) — high-risk low-grade glioma

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	aggressive
Linked regimen	`REG-RT-PCV-LGG`

ID	`IND-GLIOMA-LOW-GRADE-1L-RT-PCV`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-GLIOMA-LOW-GRADE`
Sources	`SRC-EANO-GBM-2024` `SRC-NCCN-CNS-2025`

Notes

STUB — requires clinical co-lead signoff. Closes Phase A audit gap for DIS-GLIOMA-LOW-GRADE — the disease had 0 indications. Regimen entity REG-RT-PCV-LGG not yet created.

Used By

Algorithms

ALGO-GLIOMA-LGG-1L - ALGO-GLIOMA-LGG-1L

Regimen

REG-RT-PCV-LGG - Radiotherapy + PCV (procarbazine/lomustine/vincristine) — high-risk low-grade glioma